Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- March, W.A.; Moore, V.M.; Willson, K.J.; Phillips, D.I.; Norman, R.J.; Davies, M.J. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 2009, 25, 544–551. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004, 19, 41–47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bustin, S.A.; Benes, V.; Garson, J.A.; Hellemans, J.; Huggett, J.; Kubista, M.; Mueller, R.; Nolan, T.; Pfaffl, M.W.; Shipley, G.L.; et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55, 611–622. [Google Scholar] [CrossRef] [PubMed]
- Kosus, N.; Kosus, A.; Turhan, N.O.; Kamalak, Z. Do threshold values of ovarian volume and follicle number for diagnosing polycystic ovarian syndrome in Turkish women differ from western countries? Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, 154, 177–181. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Li, L.; Chen, X.; Zhang, Q.; Wang, W.; Li, Y.; Yang, D. Ovarian volume and follicle number in the diagnosis of polycystic ovary syndrome in Chinese women. Ultrasound Obstet. Gynecol. 2008, 32, 700–703. [Google Scholar] [CrossRef]
- Durlinger, A.; Visser, J.A.; Themmen, A. Regulation of ovarian function: The role of anti-Mullerian hormone. Reproduction 2002, 124, 601–609. [Google Scholar] [CrossRef]
- Grynnerup, A.G.; Lindhard, A.; Sorensen, S. The role of anti-Mullerian hormone in female fertility and infertility—An overview. Acta Obstet. Gynecol. Scand. 2012, 91, 1252–1260. [Google Scholar] [CrossRef]
- Laven, J.S.; Mulders, A.G.; Visser, J.A.; Themmen, A.P.; De Jong, F.H.; Fauser, B.C. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J. Clin. Endocrinol. Metab. 2004, 89, 318–323. [Google Scholar] [CrossRef]
- Pigny, P.; Jonard, S.; Robert, Y.; Dewailly, D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2006, 91, 941–945. [Google Scholar] [CrossRef]
- Bhide, P.; Gudi, A.; Shah, A.; Homburg, R. Serum anti-Mullerian hormone levels across different ethnic groups: A cross-sectional study. BJOG 2015, 122, 1625–1629. [Google Scholar] [CrossRef]
- Nardo, L.G.; Yates, A.P.; Roberts, S.A.; Pemberton, P.; Laing, I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum. Reprod. 2009, 24, 2917–2923. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dewailly, D.; Gronier, H.; Poncelet, E.; Robin, G.; Leroy, M.; Pigny, P.; Duhamel, A.; Catteau-Jonard, S. Diagnosis of polycystic ovary syndrome (PCOS): Revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum. Reprod. 2011, 26, 3123–3129. [Google Scholar] [CrossRef] [PubMed]
- Sahmay, S.; Aydin, Y.; Oncul, M.; Senturk, L.M. Diagnosis of Polycystic Ovary Syndrome: AMH in combination with clinical symptoms. J. Assist. Reprod. Genet. 2014, 31, 213–220. [Google Scholar] [CrossRef] [PubMed]
- Dewailly, D.; Pigny, P.; Soudan, B.; Catteau-Jonard, S.; Decanter, C.; Poncelet, E.; Duhamel, A. Reconciling the definitions of polycystic ovary syndrome: The ovarian follicle number and serum anti-Mullerian hormone concentrations aggregate with the markers of hyperandrogenism. J. Clin. Endocrinol. Metab. 2010, 95, 4399–4405. [Google Scholar] [CrossRef]
- Tata, B.; Mimouni, N.E.H.; Barbotin, A.L.; Malone, S.A.; Loyens, A.; Pigny, P.; Dewailly, D.; Catteau-Jonard, S.; Sundstrom-Poromaa, I.; Piltonen, T.T.; et al. Elevated prenatal anti-Mullerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat. Med. 2018, 24, 834–846. [Google Scholar] [CrossRef]
- Iglesias, C.; Banker, M.; Mahajan, N.; Herrero, L.; Meseguer, M.; Garcia-Velasco, J.A. Ethnicity as a determinant of ovarian reserve: Differences in ovarian aging between Spanish and Indian women. Fertil. Steril. 2014, 102, 244–249. [Google Scholar] [CrossRef]
- Pigny, P.; Gorisse, E.; Ghulam, A.; Robin, G.; Catteau-Jonard, S.; Duhamel, A.; Dewailly, D. Comparative assessment of five serum antimullerian hormone assays for the diagnosis of polycystic ovary syndrome. Fertil. Steril. 2016, 105, 1063–1069. [Google Scholar] [CrossRef]
- Song, D.K.; Oh, J.Y.; Lee, H.; Sung, Y.A. Differentiation between polycystic ovary syndrome and polycystic ovarian morphology by means of an anti-Mullerian hormone cutoff value. Korean J. Intern. Med. 2017, 32, 690–698. [Google Scholar] [CrossRef]
- Matsuzaki, T.; Munkhzaya, M.; Iwasa, T.; Tungalagsuvd, A.; Yano, K.; Mayila, Y.; Yanagihara, R.; Tokui, T.; Kato, T.; Kuwahara, A.; et al. Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. Endocr. J. 2017, 64, 531–541. [Google Scholar] [CrossRef] [Green Version]
- Batarfi, A.A.; Filimban, N.; Bajouh, O.S.; Dallol, A.; Chaudhary, A.G.; Bakhashab, S. MC4R variants rs12970134 and rs17782313 are associated with obese polycystic ovary syndrome patients in the Western region of Saudi Arabia. BMC Med. Genet. 2019, 20, 144. [Google Scholar] [CrossRef]
- Teede, H.; Hutchison, S.; Zoungas, S.; Meyer, C. Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine 2006, 30, 45–53. [Google Scholar] [CrossRef]
- Diamanti-Kandarakis, E.; Dunaif, A. Insulin resistance and the polycystic ovary syndrome revisited: An update on mechanisms and implications. Endocr. Rev. 2012, 33, 981–1030. [Google Scholar] [CrossRef] [PubMed]
- Barthelmess, E.K.; Naz, R.K. Polycystic ovary syndrome: Current status and future perspective. Front. Biosci. 2014, 6, 104–119. [Google Scholar]
- Piouka, A.; Farmakiotis, D.; Katsikis, I.; Macut, D.; Gerou, S.; Panidis, D. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: Relationship with increased luteinizing hormone levels. Am. J. Physiol. Endocrinol. Metab. 2009, 296, E238–E243. [Google Scholar] [CrossRef]
- Wiweko, B.; Maidarti, M.; Priangga, M.D.; Shafira, N.; Fernando, D.; Sumapraja, K.; Natadisastra, M.; Hestiantoro, A. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J. Assist. Reprod. Genet. 2014, 31, 1311–1316. [Google Scholar] [CrossRef]
- La Marca, A.; Stabile, G.; Artenisio, A.C.; Volpe, A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum. Reprod. 2006, 21, 3103–3107. [Google Scholar] [CrossRef]
- Sathyapalan, T.; Al-Qaissi, A.; Kilpatrick, E.S.; Dargham, S.R.; Atkin, S.L. Anti-Mullerian hormone measurement for the diagnosis of polycystic ovary syndrome. Clin. Endocrinol. 2018, 88, 258–262. [Google Scholar] [CrossRef]
- Saxena, U.; Ramani, M.; Singh, P. Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome. J. Obstet. Gynaecol. India 2018, 68, 117–122. [Google Scholar] [CrossRef]
- Yue, C.Y.; Lu, L.K.; Li, M.; Zhang, Q.L.; Ying, C.M. Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women. PLoS ONE 2018, 13, e0203129. [Google Scholar] [CrossRef]
- Eilertsen, T.B.; Vanky, E.; Carlsen, S.M. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: Can morphologic description be replaced? Hum. Reprod. 2012, 27, 2494–2502. [Google Scholar] [CrossRef]
- Iliodromiti, S.; Kelsey, T.W.; Anderson, R.A.; Nelson, S.M. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J. Clin. Endocrinol. Metab. 2013, 98, 3332–3340. [Google Scholar] [CrossRef] [PubMed]
- Tal, R.; Seifer, D.B. Potential mechanisms for racial and ethnic differences in antimullerian hormone and ovarian reserve. Int. J. Endocrinol. 2013, 2013, 818912. [Google Scholar] [CrossRef] [PubMed]
- Bragg, J.M.; Kuzawa, C.W.; Agustin, S.S.; Banerjee, M.N.; McDade, T.W. Age at menarche and parity are independently associated with Anti-Mullerian hormone, a marker of ovarian reserve, in Filipino young adult women. Am. J. Hum. Biol. 2012, 24, 739–745. [Google Scholar] [CrossRef] [PubMed]
- Kerkhof, G.F.; Leunissen, R.W.; Willemsen, R.H.; de Jong, F.H.; Visser, J.A.; Laven, J.S.; Hokken-Koelega, A.C. Influence of preterm birth and small birth size on serum anti-Mullerian hormone levels in young adult women. Eur. J. Endocrinol. 2010, 163, 937–944. [Google Scholar] [CrossRef] [PubMed]
- Tal, R.; Seifer, D.B.; Khanimov, M.; Malter, H.E.; Grazi, R.V.; Leader, B. Characterization of women with elevated antimullerian hormone levels (AMH): Correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am. J. Obstet. Gynecol. 2014, 211. [Google Scholar] [CrossRef] [PubMed]
- Cela, V.; Obino, M.E.R.; Alberga, Y.; Pinelli, S.; Sergiampietri, C.; Casarosa, E.; Simi, G.; Papini, F.; Artini, P.G. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes. Gynecol. Endocrinol. 2018, 34, 518–523. [Google Scholar] [CrossRef]
Variable | Control (n = 69) | PCOS (n = 79) | p-Value |
---|---|---|---|
Age (years) | 21 ± 3.5 | 23 ± 9 | 0.067 |
BMI (kg/m2) | 23 ± 5.94 | 25.1 ± 6.98 | 0.005 ** |
LH (IU/L) | 5.8 ± 5.2 | 8.4 ± 8.55 | 0.003 ** |
FSH (IU/L) | 4.6 ± 2.75 | 4.7 ± 2.45 | 0.618 |
LH/FSH ratio | 1.2 ± 1.47 | 1.7 ± 1.79 | 0.006 ** |
AMH (ng/mL) | 2.3 ± 1.41 | 4.8 ± 4.76 | <0.0001 *** |
Clinical Characteristics | r | p-Value |
---|---|---|
Age (years) | −0.113 | 0.328 |
Age at menarche (years) | 0.324 | 0.018 * |
BMI (kg/m2) | −0.037 | 0.750 |
LH (IU/L) | 0.031 | 0.794 |
FSH (IU/L) | 0.019 | 0.870 |
LH/FSH ratio | 0.073 | 0.540 |
Clinical Symptoms | AMH ≥ 3.19 | AMH < 3.19 | p-Value |
---|---|---|---|
PCOM (Yes/No) | 55/2 | 18/4 | 0.048 |
OA (Yes/No) | 44/13 | 22/0 | 0.015 |
HA (Yes/No) | 39/13 | 16/6 | 1.000 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ahmed, N.; Batarfi, A.A.; Bajouh, O.S.; Bakhashab, S. Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms. Diagnostics 2019, 9, 136. https://doi.org/10.3390/diagnostics9040136
Ahmed N, Batarfi AA, Bajouh OS, Bakhashab S. Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms. Diagnostics. 2019; 9(4):136. https://doi.org/10.3390/diagnostics9040136
Chicago/Turabian StyleAhmed, Nada, Asma A. Batarfi, Osama S. Bajouh, and Sherin Bakhashab. 2019. "Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms" Diagnostics 9, no. 4: 136. https://doi.org/10.3390/diagnostics9040136